Every Form 4 that Arvinas, Inc (ARVN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARVN filings page.
ARVINAS, INC. director Laurie Smaldone Alsup reported equity awards consisting of restricted stock units and stock options. She was granted 15,527 RSUs, each representing a right to receive one share of common stock for no cash consideration upon settlement. Following this award, she directly holds 41,572 shares of common stock. She also received stock options covering 22,714 shares of common stock at an exercise price of $8.05 per share. Both the RSUs and the options vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to her continued service with Arvinas.
ARVINAS, INC. director Leslie V. Norwalk reported routine equity compensation awards, not open-market trading. On June 24, 2026, Norwalk received 15,527 restricted stock units, each representing a right to one share of common stock for no cash payment, bringing direct common stock holdings to 41,572 shares.
Norwalk was also granted an option to buy 22,714 shares of common stock at an exercise price of $8.0500 per share, expiring on June 23, 2036. Both the RSUs and the option vest in full on June 24, 2027 or immediately before the first annual stockholder meeting after the grant date, if service with the company continues through vesting.
ARVINAS, INC. director Briggs Morrison reported equity awards consisting of restricted stock units and stock options. He received 15,527 shares of common stock as RSUs and 22,714 stock options with an exercise price of $8.05 per share. Following the grants, he directly holds 111,548 common shares and 22,714 options. The RSUs and options vest in full on the earlier of June 24, 2027 or immediately before the first annual stockholders’ meeting after the grant date, subject to his continued service with the company.
ARVINAS, INC. director Edward M. Kennedy Jr. reported new equity awards in the form of restricted stock units and stock options. He received 15,527 restricted stock units, each representing one share of common stock for no cash consideration upon settlement, and a stock option covering 22,714 shares at an exercise price of $8.05 per share.
Both the RSUs and the option were granted on June 24, 2026 and will vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to his continued service with Arvinas. After these awards, he holds 54,957 shares of common stock directly and 29,333 shares indirectly through the Edward M. Kennedy Jr. 2011 Trusts For Children.
Arvinas, Inc. director Everett Cunningham reported equity awards made on June 24, 2026. He received 15,527 restricted stock units, each representing one share of common stock at no cost upon settlement, and a stock option for 22,714 shares at an exercise price of $8.05 per share, expiring on June 23, 2036. Both awards vest in full on the earlier of June 24, 2027 or immediately before the first annual stockholders’ meeting after the grant, subject to his continued service. Following these awards, Cunningham directly holds 41,572 shares of common stock.
Arvinas, Inc. granted equity awards to director Linda Bain. She received 15,527 restricted stock units, each representing one share of common stock for no cash consideration. Following the grant, she directly holds 41,572 common shares.
Bain was also granted stock options for 22,714 shares at an exercise price of $8.05 per share, expiring on June 23, 2036. Both the RSUs and options vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to her continued service with Arvinas.
ARVINAS, INC. Chief Financial Officer Andrew Saik reported an automatic sale of 5,696 shares of common stock at $8.159 per share. The sale was made by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on June 24, 2024, under a durable sale instruction, and was not a discretionary trade. After this transaction, he continues to hold 187,432 shares of common stock directly.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of 2,576 shares of common stock at $7.595 per share. According to the disclosure, the issuer executed this sale to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, under a durable sale instruction, and it was not a discretionary trade. Following the transaction, Cacace directly holds 180,390 shares of Arvinas common stock.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 2,209 shares of common stock at $9.0365 per share. According to the footnote, the shares were sold by the company to cover tax withholding obligations tied to the vesting of RSUs granted on May 21, 2024, and the transaction was not a discretionary trade. After this tax-related sale, Teel directly holds 285,009 shares of Arvinas common stock.
Arvinas, Inc.'s Chief Financial Officer Andrew Saik reported an automatic sale of 11,139 shares of common stock at $9.9374 per share. The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on May 9, 2025, and the transaction was not a discretionary trade. After this sale, Saik directly holds 193,128 shares of Arvinas common stock.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, had 1,919 shares of common stock sold on May 11, 2026 at $9.9374 per share. According to the footnote, this automatic sale by the company covered tax withholding on vested RSUs and was not a discretionary trade. After this transaction, Loomis directly holds 40,193 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic share sale tied to tax withholding. On May 11, 2026, she sold 9,657 shares of common stock at $9.9374 per share. According to the footnote, this sale was made by the company to cover tax obligations from the vesting and settlement of RSUs granted on May 9, 2025 and "does not represent a discretionary trade." After the transaction, she directly owned 182,966 shares of Arvinas common stock.
Arvinas, Inc.’s Chief Medical Officer, Noah Berkowitz, reported a sale of 11,108 shares of common stock at an average price of $9.9374 per share on May 11, 2026. According to the filing, the sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of half of his RSUs granted on May 9, 2025, and is not a discretionary trade. Following this tax-related sale, Berkowitz directly holds 191,395 shares of Arvinas common stock.
ARVINAS, INC. reported that President and CEO Randy Teel had 9,657 shares of Common Stock sold on May 11, 2026 at an average price of $9.9374 per share.
According to the disclosure, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of restricted stock units granted on May 9, 2025, and is not a discretionary trade. Following the transaction, Teel directly holds 287,218 shares of Arvinas common stock.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic share disposition related to tax withholding. On March 18, he sold 6,435 shares of common stock at an average price of $11.1004 per share. According to the footnote, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on March 18, 2024, and did not represent a discretionary trade. After this transaction, he directly held 202,503 shares of Arvinas common stock.
Teel Randy reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. President and CEO Randy Teel reported an amended equity award, correcting the size of a previously disclosed grant of restricted stock units (RSUs) made on February 26, 2026.
The corrected grant covers 147,179 RSUs, each representing one share of common stock for no cash payment, under the company’s 2018 Stock Incentive Plan. The RSUs vest in four equal annual installments on February 12 of 2027, 2028, 2029 and 2030, contingent on his continued service. Following this correction, Teel is shown as beneficially owning 296,875 shares after the reported transaction.
The amendment fixes an earlier clerical error that had misstated the award as 147,791 RSUs and adjusts the reported post-transaction holdings to match the accurate grant amount.
Arvinas, Inc. director Briggs Morrison reported an open-market purchase of 20,000 shares of the company’s common stock. The transaction took place on March 6, 2026 at a weighted average price of $13.4035 per share, and increased his direct holdings to 96,021 shares. A footnote explains that the purchase price is a weighted average of multiple trades executed between $13.364 and $13.45 per share.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, reported equity awards granted on February 26, 2026. He acquired a stock option for 18,504 shares and a grant of 12,420 shares of common stock, both at an exercise/issuance price of $0.00 per share.
The 12,420 restricted stock units each represent one future share of common stock and will vest in four equal annual installments on February 26, 2027, 2028, 2029, and 2030, subject to his continued service. The 18,504 option shares vest over four years: one quarter on February 26, 2027, with the remaining shares vesting in equal monthly installments through February 26, 2030, also contingent on continued service.
Cacace Angela M reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. reported that Chief Scientific Officer Angela M. Cacace received new equity awards on February 26, 2026. She was granted options to purchase 67,000 shares of common stock and 45,000 restricted stock units, each RSU representing one share upon settlement for no cash payment.
The RSUs vest in four equal annual installments on February 26 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options also vest over four years, with 25% vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments through February 26, 2030, subject to ongoing employment.
ARVINAS, INC. reported that Chief Medical Officer Noah Berkowitz received new equity awards. He was granted stock options for 67,000 shares at an exercise price of $0.0000 per share and 45,000 restricted stock units, each representing one share of common stock upon settlement for no consideration.
The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued service. The option also vests over four years, with one-quarter vesting on February 26, 2027 and the remainder in equal monthly installments through February 26, 2030. Following these grants, Berkowitz directly owns 208,938 shares of common stock.
Saik Andrew reported acquisition or exercise transactions in this Form 4 filing.
Arvinas, Inc. reported that its Chief Financial Officer, Andrew Saik, received equity awards on February 26, 2026. He was granted options to purchase 67,000 shares and 45,000 restricted stock units, both at no cash cost, vesting gradually over four years, contingent on continued service.
Arvinas, Inc. President and CEO Randy Teel reported equity awards from the company. He received a stock option for 218,691 shares at an exercise price of $0.00 per share and a grant of 147,791 restricted stock units, each settling into one common share if vesting conditions are met. Both awards vest over four years starting on February 12, 2027, contingent on his continued service.
Arvinas, Inc. director John G. Houston reported selling a total of 35,297 shares of common stock on February 27, 2026 in three open‑market transactions at prices between $13.14 and $13.24 per share.
According to the footnotes, each sale was made automatically by Arvinas to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, and the sales did not represent discretionary trades. After these transactions, Houston directly owned 1,122,183 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock tied to tax withholding. On February 23, he sold 1,108 shares of Arvinas common stock at $12.16 per share. The sale was made by the company to cover tax obligations arising from the vesting and settlement of one-half of his restricted stock units granted on February 23, 2024, and did not represent a discretionary trade. After this transaction, Loomis directly holds 29,692 Arvinas common shares.
ARVINAS, INC. Chief Scientific Officer Angela M. Cacace reported automatic sales of a total of 3,609 shares of common stock at $12.16 per share. These transactions were made by the company to cover tax withholding on vesting restricted stock units and did not represent discretionary trades.
Arvinas, Inc. President and CEO Randy Teel reported two open-market sales of common stock linked to equity award vesting. On February 23, 2026, he sold 1,038 shares and 3,748 shares at $12.16 per share, totaling 4,786 shares.
According to the footnotes, both sales were made automatically by the company to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on February 22, 2023 and February 23, 2024, and do not represent discretionary trades.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 4,403 shares of common stock on February 13, 2026 at $11.89 per share. According to the filing, the issuer executed this sale solely to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2026, and it was not a discretionary trade. Following this transaction, Teel beneficially owned 154,482 shares of Arvinas common stock directly.
Arvinas, Inc.’s Chief Financial Officer Andrew Saik reported an automatic share sale related to tax withholding. On February 13, 2026, 5,134 shares of common stock were sold at $11.89 per share to cover tax obligations triggered by the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The filing notes this was not a discretionary trade. After this transaction, Saik’s directly held stake is 159,267 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding. On February 13, 2026, 4,592 shares of common stock were sold in an open-market transaction at $11.89 per share to cover tax obligations from RSU vesting. After this transaction, Cacace directly owned 151,232 common shares, which include 1,576 shares previously acquired under the company’s 2018 Employee Stock Purchase Plan. The filing notes the sale did not represent a discretionary trade.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic sale of 5,685 shares of common stock at $11.89 per share. The shares were sold by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The transaction was not a discretionary trade. After this sale, Berkowitz directly holds 163,938 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock to cover taxes tied to restricted stock units. On February 13, he sold 1,016 shares of common stock at an average price of $11.89 per share in an open-market transaction.
The footnotes explain this sale was made by the company to satisfy tax withholding obligations upon vesting and settlement of 25% of RSUs granted on February 13, 2025, and that it was not a discretionary trade. After this sale, Loomis directly owns 30,800 shares, including 119 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas (ARVN) insider update: Chief Accounting Officer David K. Loomis reported a sale of 230 shares of common stock on 11/07/2025 at $9.89 per share. The filing states the sale was made automatically by the company to cover tax withholding tied to the vesting and settlement of 25% of RSUs granted on December 13, 2022.
Following the transaction, Loomis beneficially owns 31,697 shares directly. This total includes 1,239 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.